Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
A significant and nonsignificant increase, with regression coefficients of 71579.4 and 814.1 regarding the number of prescriptions for serum vitamin D and serum calcium tests, respectively, was highlighted.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This cross-sectional study evaluated changes in the number of prescriptions for osteoporosis diagnosis and treatment before and during the COVID-19 pandemic from all available and complete data.
Source: Abstract.
Therefore, no informed consent was obtained since no personal or confidential data of patients was used.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The Impact of the COVID-19 Pandemic on Osteoporosis Diagnosis and Treatment in Iran: A National Study
Cross-sectional study · International Journal of Endocrinology and Metabolism · 2025
Original publication title
The Impact of the COVID-19 Pandemic on Osteoporosis Diagnosis and Treatment in Iran: A National Study
Copyright © 2025, Hajivalizadeh et al
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
This study aims to investigate the impact of the COVID-19 pandemic on osteoporosis diagnosis and treatment in Iran.
Source: ObjectivesAbstract: What methods does the paper describe?
This cross-sectional study evaluated changes in the number of prescriptions for osteoporosis diagnosis and treatment before and during the COVID-19 pandemic from all available and complete data. Data on the number of prescriptions for bone mineral density (BMD) tests, osteoporosis-related lab tests (serum vitamin D level and serum calcium level), and medications (alendronate and calcitonin) were obtained from the Iran Health Insurance Organization (IHIO) dataset from March 2019 to March 2022. Additionally, the University of Sheffield provided the number of fracture risk assessment tool (FRAX®) used with the internet protocol (IP) addresses of Iran from 2019 to 2023.
Statistical analysis was performed using the Mann-Whitney test and the interrupted time series analysis utilizing STATA. This research was carried out with the support of the Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran, under project code 1400-02-103-1177.
Source: MethodsAbstract: Results
A total number of 4,901,027 prescriptions composed of 62,718 prescriptions for BMD tests, 2,862,871 prescriptions for serum vitamin D level tests, and 1,952,600 prescriptions for serum calcium level tests regarding diagnosis, and a total number of 446,791 prescriptions, including 388,519 alendronate and 58,272 calcitonin prescriptions regarding treatment, were evaluated. A statistically significant decrease in the number of prescriptions for BMD test and FRAX® usage, with regression coefficients of -2583.3 and -410.5, respectively, was demonstrated. A significant and nonsignificant increase, with regression coefficients of 71579.4 and 814.1 regarding the number of prescriptions for serum vitamin D and serum calcium tests, respectively, was highlighted.
A statistically significant decrease in the number of prescriptions for alendronate and calcitonin, with regression coefficients of -9592.0 and -2272.3, respectively, was noted.
Source: ResultsAbstract: Conclusions
The present study demonstrated that the COVID-19 pandemic negatively affected the diagnosis and treatment of osteoporosis. However, it was limited by the lack of data on prescriptions for other osteoporosis medications and diagnostic tests, the lack of access to the data on prescriptions for people whose costs are not covered by the IHIO, and the restricted data access regarding the presented data. The findings are based on prescription-level data in Iran and primarily reflect practice within this healthcare context; therefore, caution is required when generalizing to settings with different healthcare systems or population structures.
Further studies are needed to assess this impact and to help prevent management disruption in future health crises.
Source: ConclusionsAuthors’ abstract
Background
The emergence of the COVID-19 pandemic disrupted the management of non-communicable diseases, including osteoporosis.
Objectives
This study aims to investigate the impact of the COVID-19 pandemic on osteoporosis diagnosis and treatment in Iran.
Methods
This cross-sectional study evaluated changes in the number of prescriptions for osteoporosis diagnosis and treatment before and during the COVID-19 pandemic from all available and complete data. Data on the number of prescriptions for bone mineral density (BMD) tests, osteoporosis-related lab tests (serum vitamin D level and serum calcium level), and medications (alendronate and calcitonin) were obtained from the Iran Health Insurance Organization (IHIO) dataset from March 2019 to March 2022. Additionally, the University of Sheffield provided the number of fracture risk assessment tool (FRAX®) used with the internet protocol (IP) addresses of Iran from 2019 to 2023.
Statistical analysis was performed using the Mann-Whitney test and the interrupted time series analysis utilizing STATA. This research was carried out with the support of the Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran, under project code 1400-02-103-1177.
Results
A total number of 4,901,027 prescriptions composed of 62,718 prescriptions for BMD tests, 2,862,871 prescriptions for serum vitamin D level tests, and 1,952,600 prescriptions for serum calcium level tests regarding diagnosis, and a total number of 446,791 prescriptions, including 388,519 alendronate and 58,272 calcitonin prescriptions regarding treatment, were evaluated. A statistically significant decrease in the number of prescriptions for BMD test and FRAX® usage, with regression coefficients of -2583.3 and -410.5, respectively, was demonstrated. A significant and nonsignificant increase, with regression coefficients of 71579.4 and 814.1 regarding the number of prescriptions for serum vitamin D and serum calcium tests, respectively, was highlighted.
A statistically significant decrease in the number of prescriptions for alendronate and calcitonin, with regression coefficients of -9592.0 and -2272.3, respectively, was noted.
Conclusions
The present study demonstrated that the COVID-19 pandemic negatively affected the diagnosis and treatment of osteoporosis. However, it was limited by the lack of data on prescriptions for other osteoporosis medications and diagnostic tests, the lack of access to the data on prescriptions for people whose costs are not covered by the IHIO, and the restricted data access regarding the presented data. The findings are based on prescription-level data in Iran and primarily reflect practice within this healthcare context; therefore, caution is required when generalizing to settings with different healthcare systems or population structures.
Further studies are needed to assess this impact and to help prevent management disruption in future health crises.
Publication and source details
Original title: The Impact of the COVID-19 Pandemic on Osteoporosis Diagnosis and Treatment in Iran: A National Study
Sepideh Hajivalizadeh; Mahnaz Sanjari; Kazem Khalagi; Mohammad Javad Mansourzadeh; Saeed Shahsavari; Amirhossein Aghakhani; Mohammad Effatpanah; Zahra Shahali; Fatemeh Hajivalizadeh; Pardis Zarepour; Parastoo Montazerlotf; Elahe Hesari; Noushin Fahimfar; Afshin Ostovar
International Journal of Endocrinology and Metabolism · 2025
* Corresponding Author: Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Email: mahnaz.sanjari@gmail.com** Corresponding Author: Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Email: kkhalagi@yahoo.comCopyright © 2025, Hajivalizadeh et al2025Hajivalizadeh et alhttps://creativecommons.org/licenses/by/4.0/This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:54:21.439913+00:00
DOI: 10.5812/ijem-165816 · PMC12915347